Navigation Links
RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting
Date:4/20/2017

MARLBOROUGH, Mass., April 20, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present new data from the Company's consumer product development program, based on its proprietary self-delivering RNAi (sd-rxRNA®) technology, at the Society for Investigative Dermatology (SID) 76th Annual Meeting.  The SID mission is to advance and promote the sciences relevant to skin health and disease through education, advocacy and scholarly exchange of scientific information. This annual meeting is being held April 26-29, 2017 at the Oregon Convention Center in Portland Oregon.

  • Topical Application of Self-delivering RNAi (sd-rxRNA) Compounds for Reduction of Hyperpigmentation
    RXI-231:  sd-rxRNA Targeting Tyrosinase (TYR)
    This poster will show that reduction of tyrosinase mRNA levels by sd-rxRNA in cultured cells leads to a decrease in visible pigmentation and melanin content, in line with the expected mechanism of action of an RNAi compound.  In addition, as demonstrated ex vivo in pig skin, our proprietary formulation allows for the non-invasive penetration of sd-rxRNA compounds to the epidermal dermal junction where TYR-producing melanocytes reside.  Consumer testing will initiate in May 2017.
    Date and Time: April 29, 2017 10:15 AM PDT
    Presented by:  Melissa Maxwell
    Session 3: Pigmentation and Melanoma
    Poster #: 810, Exhibit Hall A

 

  • Prevention of UVR Induced MMP1 Upregulation with an MMP1 Targeting Self-delivering RNAi (sd-rxRNA) Compound May Reduce the Effects of Skin Photo-aging
    RXI-185:  sd-rxRNA Targeting Collagenase (MMP1)
    Results from a collaboration with DSM, one of the industry's leading suppliers of ingredients and innovative solutions for beauty care products, will be presented.  This poster will show that RXI-185 is capable of reducing MMP1 mRNA levels and enzyme activity in cultured human dermal fibroblasts and in an in vitro human skin model after UVR-induced MMP1 upregulation.  In addition, Fl-RXI-185 is capable of reducing MMP1 mRNA levels following topical administration in an ex vivo human skin model.
    Date and Time: April 29, 2017 10:15 AM PDT
    Presented by:  Katherine Holton
    Session 3: Photobiology
    Poster #: 756, Exhibit Hall A

Additional information on DSM may be found by visiting their website, www.dsm.com.

RXi's consumer health compounds are intended to affect the appearance of the skin. As a consumer health product, no preventative or therapeutic claims can be made.  However, these compounds may be developed more rapidly than therapeutics and, therefore, the path to the market may be shorter and less expensive.

Both posters will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following each presentation.

About RXi's Proprietary Self-delivering RNAi (sd-rxRNA) Technology Platform

RXi's proprietary sd-rxRNA technology has many advantages over its competitors in the RNAi space.  Scientists at RXi have designed chemically-modified RNAi compounds with improved drug-like properties that are potent, stable and specific.  These proprietary compounds have built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications.  The enhanced properties of sd-rxRNA include:  efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity.  All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing.  sd-rxRNA compounds have the ability to selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas.  Our current programs include dermatology, ophthalmology and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  Additional information may be found on the Company's website, www.rxipharma.com.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-an-update-on-its-consumer-product-development-programs-at-the-society-for-investigative-dermatology-76th-annual-meeting-300442522.html


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis Ophthalmic Portfolio Market Opportunity in the U.S. Midwest
2. United States Molecular Imaging Equipment and Radiopharmaceuticals Market 2017-2023 - Research and Markets
3. Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance Discovery Platform
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
6. CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
7. Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
8. Foresee Pharmaceuticals Announces Key Executive Appointments
9. DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
10. Hi-Tech Pharmaceuticals Expands With Opening of West Coast Distribution Center
11. Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... , May 3, 2017  West Pharmaceutical Services, ... solutions for injectable drug administration, announced today that ... and Technical Services, and Diane Paskiet , ... offering presentations focused on West,s expertise in the ... as well as providing commentary on updated industry ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... 2017 , ... Axiad IDS , a leading provider of trusted identities ... the company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this ... and proactively address potential cybersecurity threats before they happen. The annual list ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... a 2017 Best in KLAS category winner, has named Daniel P. Bullington as ... and enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and ... in Las Vegas, NV, and the importance of treating it immediately. They ... leading care for peri-implantitis, with or without a referral. As experienced periodontists and ...
(Date:5/23/2017)... ... ... New patients with symptoms of gum disease in San Diego, ... treatments from the doctors at Art of Dentistry, without first receiving a referral. Drs. ... of receiving qualified treatment in order to avoid systemic health effects associated with untreated ...
(Date:5/22/2017)... Mt. Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced ... can be administered for a variety of treatments. One or more sedation methods may ...
Breaking Medicine News(10 mins):